A Phase 1a/1b Safety and Tolerability Study of FPT155 in Patients with Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2018
At a glance
- Drugs FPT 155 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Five Prime Therapeutics
- 14 Nov 2018 According to a Five Prime Therapeutics media release, the company has initiated patient dosing in this trial.
- 14 Nov 2018 Status changed from planning to recruiting, according to a Five Prime Therapeutics media release.
- 21 Aug 2018 New trial record